| Literature DB >> 29753381 |
Sohail Abdul Salim1, Lakshmi Ramachandran Nair2, Litty Thomas3, Vishnu Garla2, Venkataraman Palabindala4, Mohit Agarwal3, Tibor Fülöp5.
Abstract
Denosumab is a monoclonal antibody directed against the receptor activator of nuclear factor kappa B ligand (RANKL). Denosumab has been shown to reduce the risk of skeletal-related events, including spinal cord compression, pathologic fracture and hypercalcemia of malignancy in patients with bone metastases. Hypocalcemia is a known side effect of denosumab, occurring in an estimated 8-14% of the patients. Here, we present an asymptomatic patient with stage-5 chronic kidney disease and severe hypocalcemia who had received denosumab 1 month earlier.Entities:
Keywords: Alkaline phosphatase; End-stage renal disease; Hypercalcemia of malignancy; Parathyroid hormone; RANKL inhibitor
Mesh：
Substances：
Year: 2017 PMID： 29753381 DOI： 10.1016/j.amjms.2017.09.008
Source DB: PubMed Journal: Am J Med Sci ISSN： 0002-9629 Impact factor: 2.378